Members of the International Society of Geriatric Oncology (SIOG) task force searched Medline and PubMed in English for “prostate cancer”, “neoplasms”, “elderly”, and “age limit >70 years”, focusing preferentially on 2009–13. American Urological Association (AUA), European Association of Urology (EAU), European Society for Medical Oncology (ESMO), and National Comprehensive Cancer Network (NCCN) guidelines were consulted from the respective bodies' websites. EAU, AUA, American Society of
ReviewManagement of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology
Introduction
Prostate cancer is the most frequently diagnosed male cancer in both the USA1 and Europe,2 and one of the three most common causes of cancer-related death.1 It is predominantly a disease of older men, with a median age at diagnosis of 66 years; 70% of deaths due to prostate cancer occur in men aged 75 years or older. The burden of the disease is expected to increase with the ageing of the population.
Available treatment guidelines make few specific recommendations for older men with prostate cancer.3, 4, 5, 6 In 2010, the International Society of Geriatric Oncology (SIOG) undertook a systematic bibliographical search of procedures and treatment options for localised and advanced prostate cancer to develop recommendations for the management of older men with prostate cancer.7, 8 Recommendations from the 2013 European Association of Urology (EAU) guidelines,6 which include chapters on the treatment of prostate cancer in older men and on issues related to quality of life, accord with the 2010 SIOG guidelines.7, 8 Both highlight the under-treatment of older men, and the importance of assessing health status and comorbidities in management decisions. The recent EAU recommendations on early detection of prostate cancer specify that screening for prostate-specific antigen (PSA) should be offered to any man with a life expectancy of at least 10 years.9
The previously published SIOG guidelines7, 8 stated that age alone should not the provision of preclude effective treatment for prostate cancer. The aim of this report is to provide physicians with an updated comprehensive summary of evidence-based recommendations, including specific decision-making algorithms, for the management of localised and advanced prostate cancer in men older than 70 years. These care decisions should be made while taking into account patient preference.
Section snippets
Assessment of life expectancy, comorbidities, and health status
Although life expectancy is a major determinant of the potential benefit from therapy, it varies substantially between individuals of the same age. For example, the median life expectancy for a 75-year-old man is 8 years, but the individual's life expectancy will depend on other factors, such as comorbidities. Men in the highest quartile (likely to be healthy individuals) will live at least 14 years, whereas those in the lowest quartile (frail individuals with substantial comorbidities) will
Comorbidities
Comorbidities, as measured by the Charlson index,17 are major predictors of survival, after the exclusion of death from prostate cancer.11 The Cumulative Illness Score Rating-Geriatrics (CISR-G) is the best available method to assess the risk of non-prostate-cancer death;17 it rates non-lethal conditions according to their severity and potential degree of control by treatment (where grade 0 equates to no condition whereas grade 4 equates to an extremely severe condition requiring immediate
Treatment of prostate cancer Background
The SIOG Prostate Cancer Working Group examined the standard approaches for the management and treatment of localised and advanced prostate cancer, and applied, when possible, evidence-based considerations specific to a senior adult population. Retrospective studies of treatment for localised prostate cancer have focused mainly on patients in good health or fitness. In trials with chemotherapeutic agents and new hormone-targeted treatments that have shown the same benefit in elderly patients as
Treatment decisions
The aim of treatment for localised prostate cancer (T1–3, N0, M0 disease) is generally curative. Treatment decisions in older men with localised prostate cancer should take into account the risk of dying from the cancer (which depends on its grade and stage), the risk of dying from another cause (which depends more on the severity of comorbidities than on age), potential treatment risks, and the patient's preferences.
Treatment decisions should also take into account the risk of developing
Androgen deprivation therapy
This approach is the mainstay of treatment for patients with metastatic prostate cancer. Castration by surgery, or through use of agonists or antagonists of luteinising-hormone releasing hormone (LHRH), is the standard first-line treatment. No difference in efficacy between these treatments has been established. The standard procedure for second-line hormonal treatment is cessation of antiandrogen therapy (if given as first-line treatment in association with an LHRH agonist). No established
Early diagnosis of prostate cancer
The screening policy in older men with prostate cancer is controversial. Individual early diagnosis decisions should be based on the patient's health status, not on age. Two other important factors to be taken into account when screening are the increasing incidence of aggressive prostate cancer with increased age, and a patient's wish to be screened. Most guidelines do not recommend routine PSA screening in men aged 70 years or older or in any man with a life expectancy of less than 10 years.5
Conclusion
On the basis of the recommendations of the SIOG Prostate Cancer Working Group, and other international bodies, older patients with prostate cancer should be managed according to their individual health status, which is driven mainly by the severity of associated comorbid conditions, and not by patient's age. Screening for health status should include a validated screening instrument (G8), and the assessment of comorbid disorders (CISR-G scale), dependence status (IADL and ADL scales), and
Search strategy and selection criteria
References (79)
- et al.
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012
Eur J Cancer
(2013) - et al.
Castration-resistant prostate cancer: AUA Guideline
J Urol
(2013) - et al.
Prostate cancer: ESMO Consensus Conference Guidelines 2012
Ann Oncol
(2013) - et al.
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults
Crit Rev Oncol Hematol
(2010) - et al.
Early detection of prostate cancer: European Association of Urology recommendation
Eur Urol
(2013) - et al.
Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)
Crit Rev Oncol Hematol
(2005) - et al.
Evaluation of the Groningen Frailty Indicator and the G8 questionnaire as screening tools for frailty in older patients with cancer
J Geriatr Oncol
(2013) - et al.
Screening older cancer patients: first evaluation of the G-8 geriatric screening tool
Ann Oncol
(2012) - et al.
Undernutrition in elderly patients with cancer: target for diagnosis and intervention
Crit Rev Oncol Hematol
(2008) - et al.
Statements on the interdependence between the oncologist and the geriatrician in geriatric oncology
Crit Rev Oncol Hematol
(2004)
A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance
J Urol
Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer
Eur Urol
Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification
J Sex Med
Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome
Int J Radiat Oncol Biol Phys
Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study
Eur Urol
Guideline for the management of clinically localized prostate cancer: 2007 update
J Urol
Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes
J Urol
Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis
Eur Urol
A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006
Eur Urol
Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies
J Urol
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
Lancet Oncol
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial
Lancet Oncol
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31
Int J Radiat Oncol Biol Phys
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
Lancet Oncol
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study
Lancet Oncol
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)
Eur Urol
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction
Int J Radiat Oncol Biol Phys
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Lancet Oncol
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Lancet
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
Ann Oncol
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Lancet Oncol
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Lancet Oncol
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Lancet
Cancer statistics, 2013
CA Cancer J Clin
NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline): prostate cancer
Guidelines on prostate cancer
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology
BJU Int
Cancer screening in elderly patients: a framework for individualized decision making
JAMA
Impact of comorbidity on survival among men with localized prostate cancer
J Clin Oncol
Cited by (180)
Management of Localized T1c Prostate Cancer Among Men 75 Years and Older: A National Cancer Database Study
2023, Clinical Genitourinary CancerSymptom experiences of older adults during treatment for metastatic prostate cancer: A qualitative investigation
2023, Journal of Geriatric OncologyComparison of 2-Weekly and 3-Weekly Dosing of Docetaxel in Metastatic Prostate Cancer
2022, Clinical Genitourinary CancerIrradiation of localized prostate cancer in the elderly: A systematic literature review
2022, Clinical and Translational Radiation Oncology
- †
Prof Fitzpatrick died May 14, 2014